This CPB is revised to state that factor X (Coagadex) is considered medically necessary for adults and children with hereditary Factor X deficiency for: 1) on-demand treatment and control of bleeding episodes in persons with moderate to severe Factor X deficiency (FX:C < 5 IU/dL); or 2) perioperative management of bleeding in patients with mild hereditary Factor X deficiency. This CPB is revised to state that pegylated recombinant factor VIII (Adynovate) is considered medically necessary to prevent or treat hemorrhagic complications in adults and children with hemophilia A when criteria are met. This CPB is revised to state that recombinant von Willebrand factor (Vonvendi) is considered medically necessary for treatment of spontaneous and/or trauma-induced bleeding episodes in individuals with severe von Willebrand disease (VWD), or individuals with mild or moderate VWD when there is failure, contraindication or intolerance to desmopressin.